Morbidity after left trisectionectomy for hepato‐biliary malignancies: An analysis of the National Clinical Database of Japan
Journal of Hepato-Biliary-Pancreatic Sciences · 2023-12 · 30 (12) · 1304-1315
DOI: 10.1002/jhbp.1358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, online erschienen am 26.09.2023. Verfasst von Fumihiro Terasaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan. Hauptthemen laut MEDLINE: Blood Loss, Surgical, Biliary Tract Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
The aim of this study was to analyze the nationwide surgical outcome of a left trisectionectomy (LT) and to identify the perioperative risk factors associated with its morbidity.
Methods
Cases of LT for hepato‐biliary malignancies registered at the Japanese National Clinical Database between 2013 and 2019 were retrospectively reviewed. Statistical analyses were performed to identify the perioperative risk factors associated with a morbidity of Clavien–Dindo classification (CD) ≥III.
Results
Left trisectionectomy was performed on 473 and 238 cases of biliary and nonbiliary cancers, respectively. Morbidity of CD ≥III and V occurred in 45% and 5% of cases with biliary cancer, respectively, compared with 26% and 2% of cases with nonbiliary cancer, respectively. In multivariable analyses, biliary cancer was significantly associated with a morbidity of CD ≥III (odds ratio, 1.87; p = .018). In subgroup analyses for biliary cancer, classification of American Society of Anesthesiologists physical status (ASA‐PS) 2, portal vein resection (PVR), and intraoperative blood loss ≥30 mL/kg were significantly associated with a morbidity of CD ≥III.
Conclusions
Biliary cancer induces severe morbidity after LT. The ASA‐PS classification, PVR, and intraoperative blood loss indicate severe morbidity after LT for biliary cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Endowed Course for Health System Innovation, Keio University School of Medicine, Tokyo, Japan.
- Project Management Subcommittee, The Japanese Society of Gastroenterological Surgery, Tokyo, Japan.
- Department of Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan.
- Database Committee, The Japanese Society of Gastroenterological Surgery, Tokyo, Japan.
ORCID-Profile: Fumihiro Terasaki, Teiichi Sugiura, Atsushi Nanashima, Shohei Komatsu, Itaru Endo
Zitieren
APA
Terasaki, F., Hirakawa, S., Tachimori, H., Sugiura, T., Nanashima, A., Komatsu, S., Miyata, H., Kakeji, Y., Kitagawa, Y., Nakamura, M., & Endo, I. (2023). Morbidity after left trisectionectomy for hepato‐biliary malignancies: An analysis of the National Clinical Database of Japan. Journal of Hepato-Biliary-Pancreatic Sciences, 30(12), 1304-1315. https://doi.org/10.1002/jhbp.1358
Vancouver
Terasaki F, Hirakawa S, Tachimori H, Sugiura T, Nanashima A, Komatsu S, et al. Morbidity after left trisectionectomy for hepato‐biliary malignancies: An analysis of the National Clinical Database of Japan. Journal of Hepato-Biliary-Pancreatic Sciences. 2023;30(12):1304-1315. doi:10.1002/jhbp.1358
BibTeX
@article{Terasaki2023,
author = {Terasaki, Fumihiro and Hirakawa, Shinya and Tachimori, Hisateru and Sugiura, Teiichi and Nanashima, Atsushi and Komatsu, Shohei and Miyata, Hiroaki and Kakeji, Yoshihiro and Kitagawa, Yuko and Nakamura, Masafumi and Endo, Itaru},
title = {Morbidity after left trisectionectomy for hepato‐biliary malignancies: An analysis of the National Clinical Database of Japan},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2023},
volume = {30},
number = {12},
pages = {1304--1315},
doi = {10.1002/jhbp.1358}
}
EUVIMED